Autor: |
Yi-Ping Hsieh, Yun-Ju Wang, Ling-Yi Feng, Li-Tzy Wu, Jih-Heng Li |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
International Journal of Environmental Research and Public Health. 19:8363 |
ISSN: |
1660-4601 |
DOI: |
10.3390/ijerph19148363 |
Popis: |
Background: Mifepristone (RU-486) has been approved for abortion in Taiwan since 2000. Mifepristone was the first non-addictive medicine to be classified as a schedule IV controlled drug. As a case of the “misuse” of “misuse of drugs laws,” the policy and consequences of mifepristone-assisted abortion for pregnant women could be compared with those of illicit drug use for drug addicts. Methods: The rule-making process of mifepristone regulation was analyzed from various aspects of legitimacy, social stigma, women’s human rights, and access to health care. Results and Discussion: The restriction policy on mifepristone regulation in Taiwan has raised concerns over the legitimacy of listing a non-addictive substance as a controlled drug, which may produce stigma and negatively affect women’s reproductive and privacy rights. Such a restriction policy and social stigma may lead to the unwillingness of pregnant women to utilize safe abortion services. Under the threat of the COVID-19 pandemic, the US FDA’s action on mifepristone prescription and dispensing reminds us it is time to consider a change of policy. Conclusions: Listing mifepristone as a controlled drug could impede the acceptability and accessibility of safe mifepristone use and violates women’s right to health care. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|